GSK fires former R&D chief Slaoui after sexual harassment allegation
Centessa’s founder on the new company’s unique R&D model
Verily, Novartis join fund to support Europe’s biotech entrepreneurs
The UK biotech company is putting its huge failure in allergy treatment behind it. But British venture capital leader David Grainger is highly critical of the company’s execs, and says lessons need to be learnt.
Circassia a cautionary tale for UK biotech, says Grainger